TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04717336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SODIUM CHLORIDE
Description: It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SODIUM CHLORIDE
Description: It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
Study: NCT04951856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
Study: NCT05677451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 (blinded)
Description: LOU064 (blinded) active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching active drug
Study: NCT06693687

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Metastatic Cancer
Description: Participants will be asked to to take part in a research study because you have metastatic cancer (meaning that your cancer has spread to other parts of the body) and will be starting systemic therapy.
Study: NCT06692426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyoPAXon
Description: MyoPAXon is a CD54+ allogeneic muscle progenitor cell product derived from the iPSC line LiPSC-ER2.2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyoPAXon
Description: MyoPAXon is a CD54+ allogeneic muscle progenitor cell product derived from the iPSC line LiPSC-ER2.2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyoPAXon
Description: MyoPAXon is a CD54+ allogeneic muscle progenitor cell product derived from the iPSC line LiPSC-ER2.2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyoPAXon
Description: MyoPAXon is a CD54+ allogeneic muscle progenitor cell product derived from the iPSC line LiPSC-ER2.2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (Prograf) is an immunosuppressant that inhibits calcineurin and T cell activation, and is commonly used to prevent solid organ transplant rejection1 and graft versus host disease (GVHD) as well as allograft rejection in the setting of allogeneic hematopoietic stem cell transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (Prograf) is an immunosuppressant that inhibits calcineurin and T cell activation, and is commonly used to prevent solid organ transplant rejection1 and graft versus host disease (GVHD) as well as allograft rejection in the setting of allogeneic hematopoietic stem cell transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (Prograf) is an immunosuppressant that inhibits calcineurin and T cell activation, and is commonly used to prevent solid organ transplant rejection1 and graft versus host disease (GVHD) as well as allograft rejection in the setting of allogeneic hematopoietic stem cell transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (Prograf) is an immunosuppressant that inhibits calcineurin and T cell activation, and is commonly used to prevent solid organ transplant rejection1 and graft versus host disease (GVHD) as well as allograft rejection in the setting of allogeneic hematopoietic stem cell transplantation.
Study: NCT06692283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denifanstat
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablet
Study: NCT06777719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eight Treg
Description: The experimental drug Eight Treg is given to patients with a peripheral IV infusion the day before the graft (cf section 5.1.5. Infusion of the experimental drug of this protocol) in addition to the maintenance protocol combining corticosteroids, tacrolimus and MPA which are classically pre-scribed in kidney graft patients from a living donor at the Nantes CHU.
Study: NCT06777823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Rejection Task
Description: All participants will receive this
Study: NCT06418997

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBI
Description: CBI sessions follow a detailed manual to teach a group of peers cognitive and behavioral strategies that they may utilize in their daily lives, often based around the cognitive-behavioral model as a teaching tool. CBI aims to develop cognitive-behaviorally-based skills and habits in participants, such as behavioral activation, mood tracking, the identification and reframing of automatic thoughts, and assertion training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBI
Description: CBI sessions follow a detailed manual to teach a group of peers cognitive and behavioral strategies that they may utilize in their daily lives, often based around the cognitive-behavioral model as a teaching tool. CBI aims to develop cognitive-behaviorally-based skills and habits in participants, such as behavioral activation, mood tracking, the identification and reframing of automatic thoughts, and assertion training.
Study: NCT06328777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CABA-201
Description: Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Study: NCT05410145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D3S-001
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D3S-001
Description: Oral
Study: NCT06044285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UP (meals provided)
Description: This study incorporates within- and between-subject comparisons. All participants complete a series of three in-lab visits with remote data collection:~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Food is provided by the study team for 7 days in accordance with a low UP diet.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up.
Study: NCT05410145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D3S-001
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D3S-001
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous
Study: NCT06044285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UP (self-guided)
Description: Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat a low UP diet according to study provided nutritional guidance.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up.
Study: NCT05410145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intravenous
Study: NCT06044285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat as they normally do.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up.
Study: NCT05846191

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serum pentraxin 3 and high sensitive CRP
Description: serum pentraxin 3 and high sensitive CRP
Study: NCT06624969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Virtual reality program to reduce pain in orthopedic fractures
Study: NCT06694454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Description: Aerosolized azacytidine (AZA) via nebulizer on 3 consecutive days during the first week of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.~Azacytidine will be given at escalating doses in phase 1, and at the established RP2D in phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Description: Aerosolized azacytidine (AZA) via nebulizer on 3 consecutive days during the first week of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.~Azacytidine will be given at escalating doses in phase 1, and at the established RP2D in phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin (intravenous/IV), area under the serum drug concentration-time curve (AUC)=5-6 mg/mL/min based on cancer histology administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin (intravenous/IV), area under the serum drug concentration-time curve (AUC)=5-6 mg/mL/min based on cancer histology administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel (IV), 200 mg/m\^2, is administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study: NCT04717336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsules
Study: NCT06694454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel (IV), 200 mg/m\^2, is administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab (IV) administered as a flat dose of 1500 mg on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab (IV) administered as a flat dose of 1500 mg on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin (IV), 75 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin (IV), 75 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study: NCT06278506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Microwave ablation, Radiofrequency ablation, Cryo ablation
Study: NCT05258175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KT
Description: Kinesio tapping will be applied in three session and it will be changed on every fifth day in total 15 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized physiotherapy protocol
Description: 3 sets with five repetitions per day for total of 15 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized physiotherapy protocol
Description: 3 sets with five repetitions per day for total of 15 days.
Study: NCT05531084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)
Description: Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)
Description: Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components.
Study: NCT06278506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Partial or total nefrectomy
Study: NCT06061276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bTAE-HAIC
Description: bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg intravenously every 2 weeks
Study: NCT06117969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone
Description: 1.25mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiangshao granules
Description: 4g po tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone plus Xiangshao granules
Description: Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid
Study: NCT04867720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: - Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.
Study: NCT05665101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coil embolization of aneurysm sac
Description: Patients are treated with standard EVAR with additional coiling of the aneurysm sac. The distinct type of coils used is not predefined.
Study: NCT06458530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vivo
Description: Participants will meet virtually twice a week with their small group and certified trainer for 45 minutes exercise sessions for a 12-week period.
Study: NCT05807087

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional osteotomy
Description: The nasal skeleton was accessed using a closed approach or an open approach is done via a transcolumellar and infracartilaginous incision. Osteotomy was made using osteotomes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery osteotomy
Description: full exposure of the nasal bony pyramid is needed.
Study: NCT06298617

Intervention type: PROCEDURE
Intervention: Diagnostic laparoscopy
Description: All women will undergo exploratory laparoscopy under general anesthesia

Intervention type: DIAGNOSTIC_TEST
Intervention: Full Blood Count (FBC)
Description: Blood samples withdrawn from patients on EDITA tubes and gone through full blood count and differential leucocytic count
Study: NCT04852705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine (Vero Cells), Inactivated
Description: 2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
Study: NCT05705375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waterpipe size
Description: Participants will have 3 lab visits where they are allocated (random order) to smoke a small waterpipe in one visit, smoke a medium waterpipe in a second visit and smoke a large waterpipe in a third visit.
Study: NCT04871412

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 Drops
Description: 1,000 - 10,000 units daily based on serum levels for the duration of the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coriolus Versicolor
Description: 1.5g twice daily for the duration of the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trident SAP 66:33 Lemon
Description: 3g once daily for the duration of the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Pro12
Description: 12 billion colony forming units daily during the peri-operative period (approximately 1 month pre and post-surgery)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Provitalix Pure Whey Protein
Description: 1 scoop (22g) once daily during the peri-operative period (approximately 1 month pre and post-surgery) and during any adjuvant chemotherapy and radiation treatments

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theracurmin 2X
Description: 1.2g twice daily after the peri-operative period. including during adjuvant chemotherapy and radiation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea Extract
Description: 700 mg twice daily after the peri-operative period. Will not be given during adjuvant radiation or chemotherapy treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Recommendations
Description: Based on the Mediterranean diet and lower glycemic index foods
Study: NCT06779227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital family transitional nursing intervention
Description: The intervention group received a transitional care intervention mainly focused on the transitional care model (TCM).
Study: NCT06694454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine (IV), 1,250 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine (IV), 1,250 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed (IV), 500 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed (IV), 500 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study: NCT06630169

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cryopreserved AURN001
Description: Corneal Endothelial Cells and Y27632

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cryopreserved AURN001
Description: Corneal Endothelial Cells and Y27632

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cryopreserved AURN001
Description: Corneal Endothelial Cells and Y27632
Study: NCT06696040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive mobilization using a device
Description: The protocol consists of three moments: initial assessment, use of the device, and final assessment.~In the initial assessment, participants will be positioned supine on a stretcher, where the muscle tone of the lower limb(s) will be tested using the Modified Ashworth Scale. After the physical test with the Modified Ashworth Scale, the TUG test will be carried out, and, finally, gait assessment with the BAIOBIT Inertial Meter with Accelerometer and Gyroscope.~At the end of the initial assessment, the Autofisio500 device will be used. To do this, the participant will be positioned again and comfortably supine on the stretcher, and the previously tested lower limb will be attached to the device for movement, between the knee and ankle joints, for 30 minutes, at maximum speed (11 RPM).~For the final assessment, the Modified Ashowrth Scale, TUG and gait assessment with the Inertial Meter with Accelerometer and BAIOBIT Gyroscope will be applied again.
Study: NCT06696001

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: For the psychoeducation session, the focus is for the therapist to engage with the client regarding mental health broadly without a targeted effort to reinforce therapeutic alliance or to offer individualized guidance or techniques. The session will provide educational information on depression, depression symptoms and known causes, and strategies to reduce depression symptoms. The content will be delivered in a fashion to avoid individualization and psychotherapeutic exchange. The elements will focus on components of Cognitive Behavioral Therapy (CBT), differentiating between thoughts and feelings, common cognitive shortcuts, and the connection between behavior and emotion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral Activation (BA) is a psychotherapy treatment modality used for depression and focuses on replacing maladaptive coping mechanism that reinforce depressive symptoms with adaptive coping mechanisms to increase exposure to positive reinforcement. The treatment will consist of the following elements: Introduction to establish concept of positive reinforcement and build rapport, identification of client-centered values, individualized values-based activity planning and scheduling, and developing adaptive coping strategies for the future.